Navigation Links
ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
Date:5/13/2008

ion. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has internally generated several clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. ChemoCentryx's lead compound, Traficet-EN(R), a specific CCR9 antagonist, is currently in a Phase II/III multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease. CCX140, which targets the CCR2 receptor, is currently in Phase I and may subsequently be developed for diseases such as vascular restenosis, Type 2 diabetes and/or multiple sclerosis, and CCX354, a CCR1 antagonist in Phase I, is being developed for inflammatory diseases such as rheumatoid arthritis. ChemoCentryx is privately held. For more information, please refer to http://www.chemocentryx.com.

Any statements in this press release about ChemoCentryx's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as may, believe, will, expect, anticipate, estimate, intend, predict, seek, potential, continue, plan, should, could and would or the negative of these terms or other comparable terminology. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections contained in the forward-looking statements include but are not limited to (i) the initiation
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Go Healthy Initiates Additional Clinical Tests on Cholesterade
2. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
3. Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients With Relapsed Solid Tumors
4. Cara Therapeutics Initiates Phase 1 Clinical Trial of Novel Analgesic, CR845
5. Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis
6. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
7. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
8. BrainCells Inc. Initiates Phase 2 Clinical Trial with BCI-540 for Depression with Anxiety
9. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neupogen(R)
10. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
11. Texas Heart(R) Institute at St. Lukes Episcopal Hospital Initiates First Clinical Trial in the World to Treat a Heart Attack Patient with a Special Stem Cell Type
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... DALLAS and NEW YORK ... PHARMACEUTICALS, INC. (OTCBB: ACCP), has signed an exclusive, ... for the development and commercialization of its proprietary ... new corporate management team and its intention to ... Biopharmaceuticals, Inc.™, and its plans to pursue a ...
(Date:9/22/2014)... Sept. 22, 2014 Research and Markets ... Chinese Diclofenac Industry Report 2014" report to their ... Industry Report 2014 is a professional and in-depth study ... with a focus on the Chinese situation. ... including definitions, classifications, applications and industry chain structure. The ...
(Date:9/20/2014)... 20, 2014 /CNW/ - The issue: Mylan Pharmaceuticals ULC Canada, ... of its Mylan-Nitro Spray 0.4 mg/metered dose due to the ... pump component. A missing "dip tube" could ... the patient. This defect may lead patients to believe they ... to access it. Not receiving nitroglycerin could place them at ...
Breaking Medicine Technology:Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 2Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 3Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 4Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 5Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 6Global and Chinese Diclofenac Industry Report 2014 2Advisory - Mylan Pharmaceuticals recalling nitroglycerin spray due to defective pump 2
(Date:9/22/2014)... San Jose, California (PRWEB) September 22, 2014 ... densitometry is a diagnostic procedure that provides quantitative measurement ... for bone densitometers is driven by the rapidly aging ... osteoporosis and fractures. The elderly represent potential candidates for ... to structural deterioration of bone tissue as a result ...
(Date:9/22/2014)... found a way to find the proverbial needle in ... in The Journal of Experimental Medicine ... random mistakes (mutations). This process creates new versions of ... by immune cells called T cells, prompting the cells ... current ability to identify all of the mutations in ...
(Date:9/22/2014)... Researchers have found that environment has a much ... a severe, often painful food allergy that renders ... foods. , Eosinophils are normal cellular components ... too many eosinophils they can cause a variety ... inflammation and resulting tissue damage, often in the ...
(Date:9/22/2014)... an old acquaintance: a certain module of the familiar ... anchor protein. The researchers report their findings in ... into peroxisome , Peroxisomes are of vital importance ... cellular toxins. In order for them to fulfil this ... the peroxisomes first. The bulk is brought into a ...
(Date:9/22/2014)... Cancer Science Institute of Singapore (CSI Singapore) at ... an increase in a gene known as Leo1 ... acute myelogenous leukaemia (AML), increasing the incidence of ... Wee Joo, Deputy Director and Senior Principal Investigator ... University Cancer Institute, Singapore, the scientists discovered that ...
Breaking Medicine News(10 mins):Health News:Rising Incidence of Osteoporosis Spurs Growth in the Global Bone Densitometers Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Rising Incidence of Osteoporosis Spurs Growth in the Global Bone Densitometers Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Environment plays bigger role than genetics in food allergic disease eosinophilic esophagitis 2Health News:The accelerator of molecular motors 2Health News:Singapore researchers discover a gene that increases incidence of AML 2
... N.C. Some invasive procedures that are becoming increasingly common ... narrowed arteries in and around the kidneys may not be ... Forest University Baptist Medical Center. The study shows ... to a dangerous blockage in a very small percentage of ...
... is a statement from Mark Ganz, president and chief executive ... vote today on the America,s Healthy Future Act : ... economically sustainable health care reform package will be adopted this ... long-term health care security and stability for all Americans. ...
... , AARP/Blue Zones Vitality Project Inspired Residents to Make ... Minn., Oct. 13 The AARP(R)/Blue Zones(R) Vitality ... that the life expectancy of the citizens of Albert ... during the unprecedented 10-month city-wide health makeover. The ...
... Health Insurance Plans (AHIP) President and CEO Karen Ignagni ... care reform legislation in the Senate Finance Committee: , ... covers all Americans, improves quality, and puts the health ... plans have proposed guaranteed coverage, elimination of pre-existing condition ...
... , - Thomas Curran, Ph.D., FRS, is expert ... 13 A prominent scientist at ... been elected to the Institute of Medicine. Dr. Curran has ... Institute of Medicine (IOM) yesterday announced the election of 65 ...
... Speaker Nancy Pelosi issued the following statement ... committee,s health insurance reform proposal. , "The Senate Finance ... a health insurance reform bill to President Obama,s desk that ... and doctors, improve quality, and make health care affordable for ...
Cached Medicine News:Health News:Study questions need for routine intervention in patients with renovascular disease 2Health News:Study questions need for routine intervention in patients with renovascular disease 3Health News:Albert Lea Residents Add 3.1 Years of Life Expectancy 2Health News:Albert Lea Residents Add 3.1 Years of Life Expectancy 3Health News:Albert Lea Residents Add 3.1 Years of Life Expectancy 4Health News:Albert Lea Residents Add 3.1 Years of Life Expectancy 5Health News:AHIP Statement on Passage of Senate Finance Committee Legislation 2Health News:Children's Hospital Oncology Researcher Elected to Institute of Medicine 2Health News:Children's Hospital Oncology Researcher Elected to Institute of Medicine 3
... is a family of solutions that ... individuals inside hospitals, healthcare facilities, or ... The target tracking areas are networked ... of radio frequency identification (RFID) readers ...
Assetrac allows identification, location, and protection of your assets....
... The RoamAlert Integrity system builds ... ECO. All door controllers in the ... computer running a standard Windows® operating ... the use of a personal computer, ...
... uses RFID to gather patient ... departments such as surgical and ... updates of patient location to ... care events have occurred and ...
Medicine Products: